Genotoxicity refers to the property of hazardous (physical, chemical and biological) agents to cause damage to genetic information present within a cell. It is worth mentioning that this damage can lead to formation of mutations, activation of mistimed event and direct DNA damage. Further, researchers have been able to link the mutations caused by genetic toxicology to various disease indications, including several oncological and genetic disorders. In addition, it is believed that the changes introduced in the genetic material can be passed down to future cell generations. Similarly, mutagenicity refers to the introduction of perpetual transmissible changes in the genomic structure of organisms, enabling mutations in cells. Therefore, testing of genotoxicity / mutagenicity is an essential component of the safety assessment of products, with the objective of preventing certain particles from negatively impacting the human health. At present, genotoxicity tests are frequently employed across several industries, such as healthcare, chemical, cosmetic, food and agriculture, in order to determine whether a particular compound induces damage. However, since there is no particular test available for identifying all relevant genotoxic endpoints, a series of in vivo and in vitro genotoxicity testing techniques are employed to assess the safety of healthcare compounds. For instance, short-term tests (STTs), such as Ames test and micronucleus assay, determine the genotoxic potential of hazardous chemicals. These tests usually assess the safety of environmental chemicals and consumer products, as well as investigate the mode of action of suspected carcinogens. Additionally, with the rapid development of next generation sequencing technology, several new methods for genotoxicity testing have been introduced that can enable players to directly analyze the genetic materials. However, owing to the lack of required chemistry capabilities and limited in-house expertise, the stakeholders have started relying on testing service providers for assessing the safety of their compounds. Overall, the growing demand for testing of healthcare products and the stringent safety requirements established by several regulatory bodies across the globe, has created lucrative opportunities for genotoxicity / mutagenicity testing service providers.
Key Market Insights
The Genotoxicity / Mutagenicity Testing Services Market by Type of Assay (In vivo, In vitro and Non-GLP / Screening), Assay / Test Offered (Comet Assay, Micronucleus Assay, Chromosomal Aberration Test, Genetic Mutation Test and Others), End User Industry (Chemical Industry, Healthcare Industry, Agriculture Industry, Cosmetic Industry and Other Industries) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future potential of genotoxicity and mutagenicity testing services. The report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. It also answers many key questions related to this domain; some of these have been mentioned below.
What is genotoxicity and mutagenicity?
The ability of certain substances to damage genetic information is referred to as genotoxicity. It is worth mentioning that exposure to such harmful substances can lead to epigenetic alteration and genomic instability, thereby, resulting in various disease indications, such as different types of cancer.
Mutagenicity is defined as introduction of permanent transmissible changes in the structure of genetic material. These changes can affect a single gene, a group of genes, or an entire chromosome, and are linked with increasing the frequency of mutations.
What are the key advantages offered by genotoxicity testing and mutagenicity testing?
Genotoxicity and mutagenicity testing can prove beneficial in detection of potential long-term effects of substances that are introduced into the market. As a result, these tests are considered to be crucial tools for the enhancement of safety assessment of the compounds.
Which companies offer genotoxicity testing and mutagenicity testing services?
At present, more than 80 players offer a variety of assays, such as Ames assay, micronucleus assay, chromosomal aberration test, genetic mutation assay and comet assay, which can be used to evaluate the genetic toxicity of a substance. It is worth highlighting that genotoxicity / mutagenicity testing service providers primarily cater to the needs of healthcare, chemical, agriculture, cosmetic and food industries. Notable examples of the players (which have also been captured in this report) include (in alphabetic order) BioReliance, Charles River Laboratories, Eurofins Scientific, Jai Research Foundation, MB Biosciences, Syngene and Toxys.
What is the need for outsourcing genotoxicity and mutagenicity testing to contract service providers?
A number of companies currently lack the expertise related to conduct of a biological study of a compound, along with limited in-house capabilities and inadequate availability of resources, which are essential to conduct the safety assessment of products. These limitations have encouraged several organizations to outsource their genotoxicity / mutagenicity needs, in order to leverage the relevant experience and expertise of contract service providers.
How many grants have been offered for genotoxicity and mutagenicity testing?
More than 280 grants have been awarded to various organizations focused on genotoxicity / mutagenicity testing. Interestingly, majority of the grants offered in this domain are administered by National Institute of Environmental Health Sciences (NIEHS) and National Institute of Allergy and Infectious Diseases (NIAID).
What is the trend of publications related to genotoxicity and mutagenicity testing?
Over 360 articles focused on genotoxicity / mutagenicity testing have been published in high-impact journals, in the past five years. This is indicative of the substantial efforts made by researchers engaged in this domain. It is worth noting that, a considerably high share of these publications are research articles focused on evaluating the use of genetic toxicity testing in different types of compounds.
Across which key industries can genotoxicity and mutagenicity testing be utilized?
Genotoxicity / mutagenicity testing is employed in various industries, such as healthcare industry (pharmaceutical / biotechnology), chemical industry, cosmetic industry, agriculture industry and food industry.
What is the market size of genotoxicity and mutagenicity testing services?
Driven by the continuous efforts of industry stakeholders and considerable investment for exploring genetic toxicology, the genotoxicity / mutagenicity testing services market is anticipated to witness substantial growth in the foreseen future.
Scope of the Report
The study features an in-depth analysis of various firms / organizations that are engaged in this domain, across different segments.
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:
- An executive summary of the insights captured during our research, offering a high-level view on the current state of the genotoxicity and mutagenicity testing service markets and its likely evolution in the short to mid and long term.
- A general overview of genotoxicity and mutagenicity, along with information on its detrimental effects, mechanism and testing techniques employed, key applications, recent developments in the market and future perspectives.
- A detailed assessment of the overall market landscape of genotoxicity and mutagenicity testing service providers, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, type of organization, location of the facility, type of operation (genotoxicity and mutagenicity), type of offering (service, and reagents and consumables), type of assay(s) (in vitro, in vivo and Non-GLP / Screening), assay(s) / test(s) offered (Ames test, micronucleus test, chromosomal aberration test, genetic mutation assay, comet assay and others), end user industry (healthcare industry, chemical industry, agriculture industry, cosmetic industry, food industry and other industries) and type of testing system(s) (bacteria, animals and novel technology)
- An insightful benchmark analysis of various service providers segregated into three peer groups, based on location of their headquarters (North America, Europe, and Asia Pacific), highlighting the top players in this domain, in terms of their respective capabilities.
- Elaborate profiles of genotoxicity and mutagenicity service providers. Each profile includes a brief overview of the company, details related to its financial information (if available), service portfolio, recent developments and an informed future outlook.
- An in-depth analysis of various publications related to genotoxicity and mutagenicity, based on several relevant parameters, such as year of publication, type of article, popular publishers (in terms of number of publications), popular journals (in terms of number of number of publications), journal impact factor and popular journals (in terms of journal impact factor). It also includes a publication timeline analysis (by article type and journal impact factor), along with benchmarking of publications to develop more insightful opinions on the recent trends related to research and development in this area.
- A detailed review of academic grants that have been awarded to various research institutes for projects focused on genotoxicity and mutagenicity, since 2018, based on several parameters, such as year of grant award, amount awarded, funding institute centre, administering institute centre, support period, purpose of grant, activity code, type of recipient organization, location of recipient organization, study section involved, type of grant application, popular NIH departments (in terms of number of grants), prominent program officers (in terms of number of grants) and popular recipient organizations (in terms of number of grants).
- A detailed analysis of recent partnerships inked between stakeholders engaged in this domain, since 2018, based on several relevant parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships) and regional distribution of partnership activity in this domain.
- An in-depth analysis of various patents that have been filed / granted related to genotoxicity and mutagenicity, since 2018, taking into consideration parameters, such as type of patent, publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of applicant, along with a detailed patent benchmarking analysis and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
One of the key objectives of the report was to estimate the current opportunity and future growth potential of genotoxicity and mutagenicity testing services market over the coming years. We have provided informed estimates on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of assay (in vivo, in vitro and non-GLP / screening), assay / test offered (comet assay, micronucleus assay, chromosomal aberration test, genetic mutation test and others), end user industry (chemical industry, healthcare industry, agriculture industry, cosmetic industry and other industries) and key geographical regions (North America, Europe, Asia- Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is the growth rate of genotoxicity and mutagenicity testing services market?
Answer: The global market for genotoxicity and mutagenicity testing service market is expected to grow at a growth rate of 5% - 9% from 2023 to 2035.
Question 2: Which region will lead the genotoxicity and mutagenicity testing service market?
Answer: North America is anticipated to drive the market revenues, by 2035. In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace, in the long term.
Question 3: Which segment, in terms of type of assay offered, dominates the genotoxicity and mutagenicity testing service market?
Answer: Currently, in vivo assays dominate the genotoxicity and mutagenicity testing service market. However, in the foreseen future, in vitro assays are expected to influence the market with a higher share in 2035.
Question 4: Which segment, in terms of type of end users, accounts for the largest share in the genotoxicity and mutagenicity testing service market?
Answer: Chemical industries are anticipated to capture over 65% of the market share by 2035. In addition, the market for healthcare industries is likely to grow at a relatively faster pace, in the long term.
Question 5: What type of partnership models are most commonly being adopted by stakeholders engaged in this domain?
Answer: Acquisitions emerged as the most popular type of partnership model adopted by players engaged in offering genotoxicity and mutagenicity testing services. This is followed by platform licensing agreements and service alliances.
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Detrimental Effects of Genotoxins / Mutagens
3.3. Mechanism of Genotoxicity / Mutagenicity
3.4. Techniques Employed for Genotoxicity / Mutagenicity Testing
3.5. Applications of Genotoxicity / Mutagenicity
3.6. Recent Developments and Future Perspectives
4. MARKET LANDSCAPE
4.1. Genotoxicity / Mutagenicity Testing Service Providers: Overall Market Landscape
4.1.1. Analysis by Type of Operation
4.1.2. Analysis by Type of Offering
4.1.3. Analysis by Regulatory Compliance
4.1.4. Analysis by Type of Assay(s)
4.1.5. Analysis by Assay(s) / Test(s) Offered
4.1.6. Analysis by Type of Testing System(s)
4.1.7. Analysis by Custom Testing Services Offered
4.1.8. Analysis by End User Industry
4.2. Genotoxicity / Mutagenicity Testing: Service Provider Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Company Size and Type of Assay
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Type of Organization
4.2.6. Analysis by Type of Organization and Type of Assay
4.2.7. Analysis by Location of Facility
5. BENCHMARKING ANALYSIS
5.1. Scope and Methodology
5.2. Assumptions and Key Parameters
5.3. Parameters Scoring
5.4. Benchmarking Analysis: Players based in North America
5.5. Benchmarking Analysis: Players based in Europe
5.6. Benchmarking Analysis: Players based in Asia-Pacific
6. COMPANY PROFILES
6.1. Charles River Laboratories
6.1.1. Company Overview
6.1.2. Financial Information
6.1.3. Service Portfolio
6.1.4. Recent Developments and Future Outlook
6.2. LabCorp
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Syngene
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Service Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. Aurigene Pharmaceutical Services
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Sai Life Sciences
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. LSIM Safety Institute
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Future Outlook
6.7. GLR Laboratories
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook
7. PUBLICATION BENCHMARKING ANALYSIS
7.1. Scope and Methodology
7.2. Assumptions and Key Parameters
7.3. Analysis by Year of Publication
7.4. Analysis by Type of Article
7.5. Popular Journals: Analysis by Number of Publications
7.6. Popular Publishers: Analysis by Number of Publications
7.7. Analysis by Journal Impact Factor
7.8. Popular Journals: Analysis by Journal Impact Factor
7.9. Publication Timeline Analysis
7.10. Publication Benchmarking Methodology
7.11. Publication Benchmarking Analysis
7.12. List of Top 10 Publications
8. GRANTS ANALYSIS
8.1. Scope and Methodology
8.2. Assumptions and Key Parameters
8.3. Analysis by Year of Grant Award
8.4. Analysis by Amount Awarded
8.5. Analysis by Funding Institute Center
8.6. Analysis by Administering Institute Center
8.7. Analysis by Support Period
8.8. Popular Recipient Organizations: Analysis by Number of Grants
8.9. Analysis by Type of Recipient Organization
8.10. Analysis by Purpose of Grant
8.11. Analysis by Study Section
8.12. Popular NIH Departments: Analysis by Number of Grants
8.13. Analysis by Administering Institute Center and Support Period
8.14. Analysis by Type of Grant Application
8.15. Analysis by Grant Activity Code
8.16. Prominent Program Officers: Analysis by Number of Grants
8.17. Analysis by Location of Recipient Organization
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Partnership Models
9.2. Assumptions and Key Parameters
9.3. Genotoxicity / Mutagenicity Testing: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Analysis by Type of Partnership and Type of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Analysis by Region
9.3.8.1. Intercontinental and Intracontinental Deals
10. PATENT ANALYSIS
10.1. Scope and Methodology
10.2. Assumptions and Key Parameters
10.3. Genotoxicity and Mutagenicity Testing: List of Patents
10.4. Analysis by Type of Patent
10.5. Analysis by Patent Publication Year
10.6. Analysis by Annual Number of Granted Patents
10.7. Analysis by Geographical Location
10.8. Analysis by Jurisdiction
10.9. Analysis by CPC Symbols
10.10. Analysis by Type of Applicant
10.11. Analysis by Patent Age
10.12. Word Cloud: Emerging Focus Areas
10.13. Leading Industry Players: Analysis by Number of Patents
10.14. Leading Non-Industry Players: Analysis by Number of Patents
10.15. Leading Individual Assignees: Analysis by Number of Patents
10.16. Leading Players: Benchmarking by Patent Characterization (CPC Symbols)
10.17. Patent Valuation: Analysis Methodology and Parameters
10.17.1. Analysis by Relative Patent Valuation
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Genotoxicity / Mutagenicity Testing Services Market, 2023-2035
11.2.1. Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Analysis by Type of Assay
11.2.1.1. Genotoxicity / Mutagenicity Testing Services Market for In vivo Assays, 2023-2035
11.2.1.2. Genotoxicity / Mutagenicity Testing Services Market for In vitro Assays, 2023-2035
11.2.1.3. Genotoxicity / Mutagenicity Testing Services Market for Non-GLP / Screening Assays, 2023-2035
11.2.2. Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Analysis by Assay / Test Offered
11.2.2.1. Genotoxicity / Mutagenicity Testing Services Market for Comet Assays, 2023-2035
11.2.2.2. Genotoxicity / Mutagenicity Testing Services Market for Micronucleus Assays, 2023-2035
11.2.2.3. Genotoxicity / Mutagenicity Testing Services Market for Chromosomal Aberration Tests, 2023-2035
11.2.2.4. Genotoxicity / Mutagenicity Testing Services Market for Genetic Mutation Tests, 2023-2035
11.2.2.5. Genotoxicity / Mutagenicity Testing Services Market for Other Tests, 2023-2035
11.2.3. Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Analysis by End User Industry
11.2.3.1. Genotoxicity / Mutagenicity Testing Services Market for Chemical Industry 2023-2035
11.2.3.2. Genotoxicity / Mutagenicity Testing Services Market for Healthcare Industry, 2023-2035
11.2.3.3. Genotoxicity / Mutagenicity Testing Services Market for Agriculture Industry, 2023-2035
11.2.3.4. Genotoxicity / Mutagenicity Testing Services Market for Cosmetic Industry, 2023-2035
11.2.3.5. Genotoxicity / Mutagenicity Testing Services Market for Other Industries, 2023-2035
11.2.4. Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Analysis by Geographical Region
11.2.4.1. Genotoxicity / Mutagenicity Testing Services Market in North America, 2023-2035
11.2.4.2. Genotoxicity / Mutagenicity Testing Services Market in Europe, 2023-2035
11.2.4.3. Genotoxicity / Mutagenicity Testing Services Market in Asia-Pacific, 2023-2035
11.2.4.4. Genotoxicity / Mutagenicity Testing Services Market in Latin America, 2023-2035
11.2.4.5. Genotoxicity / Mutagenicity Testing Services Market in Middle East and North Africa, 2023-2035
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 3.1 Detrimental Effects on Potential Targets of Genotoxins / Mutagens
Figure 3.2 Mechanism of Genotoxicity and Mutagenicity
Figure 4.1 Genotoxicity / Mutagenicity Testing: Distribution by Type of Operation
Figure 4.2 Genotoxicity / Mutagenicity Testing: Distribution by Type of Offering
Figure 4.3 Genotoxicity / Mutagenicity Testing: Distribution by Regulatory Compliance
Figure 4.4 Genotoxicity / Mutagenicity Testing: Distribution by Type of Assay(s)
Figure 4.5 Genotoxicity / Mutagenicity Testing: Distribution by Assay(s) / Test(s) Offered
Figure 4.6 Genotoxicity / Mutagenicity Testing: Distribution by Type of Testing System(s)
Figure 4.7 Genotoxicity / Mutagenicity Testing: Distribution by Custom Testing Services Offered
Figure 4.8 Genotoxicity / Mutagenicity Testing: Distribution by End User Industry
Figure 4.9 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Year of Establishment
Figure 4.10 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Company Size
Figure 4.11 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Company Size and Type of Assay
Figure 4.12 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Location of Headquarters
Figure 4.13 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Type of Organization
Figure 4.14 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Type of Organization and Type of Assay
Figure 4.15 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Location of Facility
Figure 5.1 Company Competitiveness: Players based in North America
Figure 5.2 Benchmarking Analysis: Leading Players in North America
Figure 5.3 Company Competitiveness: Players based in Europe
Figure 5.4 Benchmarking Analysis: Leading Players in Europe
Figure 5.5 Company Competitiveness: Players based in Asia-Pacific
Figure 5.6 Benchmarking Analysis: Leading Players in Asia-Pacific
Figure 6.1 Charles River Laboratories: Financial Information
Figure 6.2 LabCorp: Financial Information
Figure 6.3 Syngene: Financial Information
Figure 6.4 Aurigene Pharmaceutical Services: Financial Information
Figure 6.5 Sai Life Sciences: Financial Information
Figure 7.1 Publication Benchmarking: Distribution by Year of Publication
Figure 7.2 Publication Benchmarking: Distribution by Type of Article
Figure 7.3 Popular Journals: Distribution by Number of Publications
Figure 7.4 Popular Publishers: Distribution by Number of Publications
Figure 7.5 Publication Benchmarking: Distribution by Journal Impact Factor
Figure 7.6 Popular Journals: Distribution by Journal Impact Factor
Figure 7.7 Publication Timeline Analysis: Distribution by Article Type
Figure 7.8 Publication Timeline Analysis: Distribution by Journal Impact Factor
Figure 7.9 Publication Benchmarking Analysis
Figure 8.1 Grants Analysis: Distribution by Year of Grant Award
Figure 8.2 Grants Analysis: Distribution by Amount Awarded
Figure 8.3 Grants Analysis: Distribution by Type of Funding Institute Center
Figure 8.4 Grants Analysis: Distribution by Type of Administering Institute Center
Figure 8.5 Grants Analysis: Distribution by Support Period
Figure 8.6 Grants Analysis: Distribution by Administering Institute Center and Support Period
Figure 8.7 Grants Analysis: Distribution by Purpose of Grant
Figure 8.8 Grants Analysis: Distribution by Grant Activity Code
Figure 8.9 Grants Analysis: Distribution by Type of Recipient Organization
Figure 8.10 Grants Analysis: Distribution by Location of Recipient Organizations
Figure 8.11 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.12 Grants Analysis: Distribution by Study Section
Figure 8.13 Grants Analysis: Distribution by Type of Grant Application
Figure 8.14 Popular NIH Departments: Distribution by Number of Grants
Figure 8.15 Prominent Program Officers: Distribution by Number of Grants
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Distribution by Region
Figure 9.9 Intercontinental and Intracontinental Deals
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Patent Publication Year
Figure 10.3 Patent Analysis: Distribution by Annual Number of Granted Patents
Figure 10.4 Patent Analysis: Distribution by Geographical Location
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Patent Analysis: Distribution by Type of Applicant
Figure 10.7 Patent Analysis: Distribution by Patent Age
Figure 10.8 Patent Analysis: Distribution by Patent Jurisdiction
Figure 10.9 Word Cloud: Emerging Focus Areas
Figure 10.10 Leading Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 10.13 Leading Players: Benchmarking by Patent Characterization (CPC Symbols)
Figure 10.14 Patent Valuation: Distribution by Relative Patent Valuation
Figure 11.1 Global Genotoxicity / Mutagenicity Testing Services Market, 20232-2035 (USD Million)
Figure 11.2 Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Distribution by Type of Assay (USD Million)
Figure 11.3 Genotoxicity / Mutagenicity Testing Services Market for In vivo Assays, 2023-2035 (USD Million)
Figure 11.4 Genotoxicity / Mutagenicity Testing Services Market for In vitro Assays, 2023-2035 (USD Million)
Figure 11.5 Genotoxicity / Mutagenicity Testing Services Market for Non-GLP / Screening Assays, 2023-2035 (USD Million)
Figure 11.6 Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Distribution by Assay / Test Offered (USD Million)
Figure 11.7 Genotoxicity / Mutagenicity Testing Services Market for Comet Assays, 2023-2035 (USD Million)
Figure 11.8 Genotoxicity / Mutagenicity Testing Services Market for Micronucleus Assays, 2023-2035 (USD Million)
Figure 11.9 Genotoxicity / Mutagenicity Testing Services Market for Chromosomal Aberration Tests, 2023-2035 (USD Million)
Figure 11.10 Genotoxicity / Mutagenicity Testing Services Market for Genetic Mutation Tests, 2023-2035 (USD Million)
Figure 11.11 Genotoxicity / Mutagenicity Testing Services Market for Other Tests, 2023-2035 (USD Million)
Figure 11.12 Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Distribution by End User Industry (USD Million)
Figure 11.13 Genotoxicity / Mutagenicity Testing Services Market for Chemical Industry, 2023-2035 (USD Million)
Figure 11.14 Genotoxicity / Mutagenicity Testing Services Market for Healthcare Industry, 2023-2035 (USD Million)
Figure 11.15 Genotoxicity / Mutagenicity Testing Services Market for Agriculture Industry, 2023-2035 (USD Million)
Figure 11.16 Genotoxicity / Mutagenicity Testing Services Market for Cosmetic Industry, 2023-2035 (USD Million)
Figure 11.17 Genotoxicity / Mutagenicity Testing Services Market for Other Industries, 2023-2035 (USD Million)
Figure 11.18 Genotoxicity / Mutagenicity Testing Services Market, 2022 and 2035: Distribution by Geographical Region (USD Million)
Figure 11.19 Genotoxicity / Mutagenicity Testing Services Market in North America, 2023-2035 (USD Million)
Figure 11.20 Genotoxicity / Mutagenicity Testing Services Market in Europe, 2023-2035 (USD Million)
Figure 11.21 Genotoxicity / Mutagenicity Testing Services Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 11.22 Genotoxicity / Mutagenicity Testing Services Market in Latin America, 2023-2035 (USD Million)
Figure 11.23 Genotoxicity / Mutagenicity Testing Services Market in Middle East and North Africa, 2023-2035 (USD Million)
List Of Tables
Table 3.1 Standard Test for Genotoxicity
Table 4.1 List of Genotoxicity / Mutagenicity Testing Service Providers
Table 6.1 Charles River Laboratories: Service Portfolio
Table 6.2 Charles River Laboratories: Recent Developments and Future Outlook
Table 6.3 LabCorp: Service Portfolio
Table 6.4 LabCorp: Recent Developments and Future Outlook
Table 6.5 Syngene: Service Portfolio
Table 6.6 Syngene: Recent Developments and Future Outlook
Table 6.7 Aurigene Pharmaceutical Services: Service Portfolio
Table 6.8 Aurigene Pharmaceutical Services: Recent Developments and Future Outlook
Table 6.9 Sai Life Sciences: Service Portfolio
Table 6.10 Sai Life Sciences: Recent Developments and Future Outlook
Table 6.11 LSIM Safety Institute: Service Portfolio
Table 6.12 LSIM Safety Institute: Future Outlook
Table 6.13 GLR Laboratories: Service Portfolio
Table 6.14 GLR Laboratories: Recent Developments and Future Outlook
Table 7.1 Genotoxicity and Mutagenicity Testing: List of Publications
Table 7.2 List of Top 10 Publications
Table 9.1 Genotoxicity / Mutagenicity Testing Services: List of Partnerships and Collaborations
Table 10.1 Genotoxicity / Mutagenicity Testing: List of Patents
Table 12.1 Genotoxicity / Mutagenicity Testing: Distribution by Type of Operation
Table 12.2 Genotoxicity / Mutagenicity Testing: Distribution by Type of Offering
Table 12.3 Genotoxicity / Mutagenicity Testing: Distribution by Regulatory Compliance
Table 12.4 Genotoxicity / Mutagenicity Testing: Distribution by Type of Assay(s)
Table 12.5 Genotoxicity / Mutagenicity Testing: Distribution by Assay(s) / Test(s) Offered
Table 12.6 Genotoxicity / Mutagenicity Testing: Distribution by Type of Testing System(s)
Table 12.7 Genotoxicity / Mutagenicity Testing: Distribution by Custom Testing Services Offered
Table 12.8 Genotoxicity / Mutagenicity Testing: Distribution by End User Industry
Table 12.9 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Year of Establishment
Table 12.10 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Company Size
Table 12.11 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Company Size and Type of Assay
Table 12.12 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Location of Headquarters
Table 12.13 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Type of Organization
Table 12.14 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Type of Organization and Type of Assay
Table 12.15 Genotoxicity / Mutagenicity Testing Service Providers: Distribution by Location of Facility
Table 12.16 Charles River Laboratories: Financial Information
Table 12.17 LabCorp: Financial Information
Table 12.18 Syngene: Financial Information
Table 12.19 Aurigene Pharmaceutical Services: Financial Information
Table 12.20 Sai Life Sciences: Financial Information
Table 12.21 Publication Benchmarking: Distribution by Year of Publication
Table 12.22 Publication Benchmarking: Distribution by Type of Article
Table 12.23 Popular Publishers: Distribution by Number of Publications
Table 12.24 Popular Journals: Distribution by Number of Publications
Table 12.25 Publication Benchmarking: Distribution by Journal Impact Factor
Table 12.26 Popular Journals: Distribution by Journal Impact Factor
Table 12.27 Grants Analysis: Distribution by Year of Grant Award
Table 12.28 Grants Analysis: Distribution by Amount Awarded
Table 12.29 Grants Analysis: Distribution by Type of Funding Institute Center
Table 12.30 Grants Analysis: Distribution by Type of Administering Institute Center
Table 12.31 Grants Analysis: Distribution by Support Period
Table 12.32 Grants Analysis: Distribution by Administering Institute Center and Support Period
Table 12.33 Grants Analysis: Distribution by Purpose of Grant
Table 12.34 Grants Analysis: Distribution by Grant Activity Code
Table 12.35 Grants Analysis: Distribution by Type of Recipient Organization
Table 12.36 Grants Analysis: Distribution by Location of Recipient Organizations
Table 12.37 Popular Recipient Organizations: Distribution by Number of Grants
Table 12.38 Grants Analysis: Distribution by Study Section
Table 12.39 Grants Analysis: Distribution by Type of Grant Application
Table 12.40 Popular NIH Departments: Distribution by Number of Grants
Table 12.41 Prominent Program Officers: Distribution by Number of Grants
Table 12.42 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.43 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.44 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.45 Partnerships and Collaborations: Distribution by Type of Partner
Table 12.46 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 12.47 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 12.48 Most Active Players: Distribution by Number of Partnerships
Table 12.49 Partnerships and Collaborations: Distribution by Region
Table 12.50 Intercontinental and Intracontinental Deals
Table 12.51 Patent Analysis: Distribution by Type of Patent
Table 12.52 Patent Analysis: Distribution by Patent Publication Year
Table 12.53 Patent Analysis: Distribution by Annual Number of Granted Patents
Table 12.54 Patent Analysis: Distribution by Geographical Location
Table 12.55 Patent Analysis: Distribution by Type of Applicant
Table 12.56 Patent Analysis: Distribution by Patent Age
Table 12.57 Patent Analysis: Distribution by Patent Jurisdiction
Table 12.58 Leading Industry Players: Distribution by Number of Patents
Table 12.50 Leading Non-Industry Players: Distribution by Number of Patents
Table 12.60 Leading Individual Assignees: Distribution by Number of Patents
Table 12.61 Leading Players: Benchmarking by Patent Characterization (CPC Symbols)
Table 12.62 Patent Valuation: Distribution by Relative Valuation
Table 12.63 Global Genotoxicity / Mutagenicity Testing Services Market, 20232-2035 (USD Million)
Table 12.64 Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Distribution by Type of Assay (USD Million)
Table 12.65 Genotoxicity / Mutagenicity Testing Services Market for In vivo Assays, 2023-2035 (USD Million)
Table 12.66 Genotoxicity / Mutagenicity Testing Services Market for In vitro Assays, 2023-2035 (USD Million)
Table 12.67 Genotoxicity / Mutagenicity Testing Services Market for Non-GLP / Screening Assays, 2023-2035 (USD Million)
Table 12.68 Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Distribution by Assay / Test Offered (USD Million)
Table 12.69 Genotoxicity / Mutagenicity Testing Services Market for Comet Assays, 2023-2035 (USD Million)
Table 12.70 Genotoxicity / Mutagenicity Testing Services Market for Micronucleus Assays, 2023-2035 (USD Million)
Table 12.71 Genotoxicity / Mutagenicity Testing Services Market for Chromosomal Aberration Tests, 2023-2035 (USD Million)
Table 12.72 Genotoxicity / Mutagenicity Testing Services Market for Genetic Mutation Tests, 2023-2035 (USD Million)
Table 12.73 Genotoxicity / Mutagenicity Testing Services Market for Other Tests, 2023-2035 (USD Million)
Table 12.74 Genotoxicity / Mutagenicity Testing Services Market, 2023-2035: Distribution by End User Industry (USD Million)
Table 12.75 Genotoxicity / Mutagenicity Testing Services Market for Chemical Industry, 2023-2035 (USD Million)
Table 12.76 Genotoxicity / Mutagenicity Testing Services Market for Healthcare Industry, 2023-2035 (USD Million)
Table 12.77 Genotoxicity / Mutagenicity Testing Services Market for Agriculture Industry, 2023-2035 (USD Million)
Table 12.78 Genotoxicity / Mutagenicity Testing Services Market for Cosmetic Industry, 2023-2035 (USD Million)
Table 12.79 Genotoxicity / Mutagenicity Testing Services Market for Other Industries, 2023-2035 (USD Million)
Table 12.80 Genotoxicity / Mutagenicity Testing Services Market, 2022 and 2035: Distribution by Geographical Region (USD Million)
Table 12.81 Genotoxicity / Mutagenicity Testing Services Market in North America, 2023-2035 (USD Million)
Table 12.82 Genotoxicity / Mutagenicity Testing Services Market in Europe, 2023-2035 (USD Million)
Table 12.83 Genotoxicity / Mutagenicity Testing Services Market in Asia-Pacific, 2023-2035 (USD Million)
Table 12.84 Genotoxicity / Mutagenicity Testing Services Market in Latin America, 2023-2035 (USD Million)
Table 12.85 Genotoxicity / Mutagenicity Testing Services Market in Middle East and North Africa, 2023-2035 (USD Million)
Companies Mentioned
- Admescope (acquired by Symeres)
- Aelan Cell Technologies
- Amelia Technologies
- Anax Laboratories
- Anthem Biosciences
- Aragen Life Sciences
- Aurigene Pharmaceutical Services
- Beijing Sun-Novo Pharmaceutical Research
- Binzhou Medical University
- BioDuro-Sundia
- Bioneeds
- BioReliance (acquired by Sigma-Aldrich)
- Bioscience Research Foundation (BRF)
- Biotrial
- Bolder BioPATH
- BRI Biopharmaceutical Research
- Brown University
- BSL BIOSERVICE
- Cadila Pharmaceuticals
- Charles River Laboratories
- Citoxlab (acquired by Charles River Laboratories)
- Creative Bioarray
- Creative Biolabs
- Crown Bioscience
- CSIR- Indian Institute of Toxicology Research
- Curza
- Cyprotex (acquired by Evotec)
- Dabur Research Foundation
- DigilenceBio
- Edara Research Foundation (ERF)
- EMTAC Laboratories (a subsidiary of Vimta Labs)
- (EBPI) Environmental Bio-Detection Products
- Eurofins Scientific
- ERBC (European Research Biology Center)
- Evotec
- Experimur
- Forschungsverbund Berlin
- Frontage Clinical Services (acquired by Frontage Laboratories)
- Frontage Laboratories
- GenEvolutioN (spin-off from Seqens)
- Gentronix
- Gerresheimer
- GLR Laboratories
- GV Research Platform
- Helix3
- University Hospital Center of Toulouse
- IIT Research Institute (IITRI)
- Inotiv
- InStem
- Integrated Laboratory Systems (acquired by Inotiv)
- International Institute of Biotechnology and Toxicology
- Intertek
- Intox (acquired by Aragen Life Sciences)
- ITR Laboratories
- Jai Research Foundation
- JDM Research
- Jubilant Chemsys
- Jubilant Life Sciences
- Kangpu Biopharmaceuticals
- Korea Research Institute of Bioscience & Biotechnology
- Korea University Research and Business Foundation
- Krish Biotech Research
- LabCorp
- LAUS
- LeadScope
- Leiden University
- Litron Laboratories
- LSIM Safety Institute
- Lupin
- Massachusetts Institute of Technology
- Max Delbrück Center for Molecular Medicine
- MB Biosciences
- MB Research Laboratories
- Medical and Biological Laboratories
- Medicilon
- Megsan Labs
- Symeres (formerly known as MercachemSyncom)
- Merck
- MilliporeSigma
- MPI Research
- Nanjing Pharmaceutical Factory
- National Autonomous University of Mexico
- National Institute for Health and Medical Research (INSERM)
- National Institute of Occupational Health
- Natural Remedies
- Nelson Labs (a subsidiary of Sotera Health)
- Nucro-Technics
- Pacific BioLabs
- Palamur Biosciences
- Paul Sabatier University
- PhoenixBio
- Pre-Clinical Research Services (acquired by Inotiv)
- PrediTox
- Profacgen
- Qilu Pharmaceutical
- RCC Laboratories
- Reliance Life Sciences
- Ribosome Research Center
- Sa-Ford
- Sai Life Sciences
- SenzaGen
- Shriram Institute for Industrial Research
- SIRO Clinpharm
- Smithers Avanza
- South China University of Technology
- Ssp
- Stallergenes Greer
- Stanford University
- Sun Pharma Advanced Research Company
- Syngene
- Taipei Medical University
- Texas Pacific Group
- Torrent Pharmaceuticals
- Toxicology Research Laboratory (a part of University of Illinois Chicago)
- Toxi-Coop
- Toxikon (acquired by LabCorp)
- Toxys
- TÜV SÜD
- TwinStrand Biosciences
- Unilever Safety and Environmental Assurance
- University of Washington
- University of California
- UT Southwestern Medical Center
- Vanta Bioscience
- Veeda Clinical Research
- Vimta Labs
- Vipragen Biosciences
- Vivo Bio Tech
- Vivotecnia
- Xenometrix
- Zhuhai Rundu Pharmaceutical
- Zyirn Research Consultancy Services
Methodology
LOADING...
